{
  "id": 20257594,
  "title": "Earnings call transcript: Jubilant Pharmova tops revenue in Q2 2026, shares rise",
  "url": "https://urgent.news/2026/11/16/earnings-call-transcript-jubilant-pharmova-tops-revenue-in-q2-2026",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T04:03:16.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-jubilant-pharmova-tops-revenue-in-q2-2026-shares-rise-93CH-5028342"
  },
  "original_language": "en",
  "account": "Jubilant Pharmova reported a 21% year-over-year rise in quarterly revenue, reaching INR 2,370 crore, with strong growth across its radiopharma, sterile injectables, allergy, and generics businesses. However, profit fell short of expectations due to remediation costs and higher operating expenses. Earnings per share (EPS) came in at 4.6, below the 5.8 expected by analysts, while revenue exceeded forecasts by INR 1.05 billion. Shares climbed 2.57% to $988.85, indicating investor optimism about the company's outlook for improving margins.\n\nRevenue for the first half of FY 2027 stood at INR 4,599 crore, up 19% year-on-year, with H1 EBITDA at INR 523 crore and profit after tax at INR 87 crore. The Montreal facility, a drag on the company, reported losses of over INR 80 crore in the quarter and cumulative losses of around INR 357 crore since the OAI issues began. Management anticipates margins to improve in the second half of the year, with H2 average EBITDA margins expected in the mid-teens.\n\nThe company expects growth in its key businesses, including the RUBY-FILL radiopharma segment and sterile injectables, to be a central part of its long-term strategy. CFO Ashish Mukkirwar reiterated the company's commitment to reducing leverage, with CapEx for FY 2028 projected to fall to about INR 1,000 crore from INR 1,800-1,900 crore in FY 2027, and a Vision 2030 target of zero net debt by the end of FY 2030. Investors seem to be more focused on the company's revenue growth and management's expectations for improving margins in the near term rather than the EPS miss.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}